Table 1 —

Demographic and clinical data on randomized patients

ParametersPlaceboMIGMETMIG + MET
n83828376
Age (years)57.7 ± 9.957.3 ± 9.057.9 ± 8.658.9 ± 7.9
Weight (kg)88.6 ± 14.191.0 ± 15.589.0 ± 17.885.6 ± 13.1
Race
 Caucasian76 (91.6)73 (89.0)73 (88.0)70 (92.1)
 Black1 (1.2)0 (0.0)1 (1.2)3 (3.9)
 Asian4 (4.8)4 (4.9)6 (7.2)3 (3.9)
 Other2 (2.4)5 (6.1)3 (3.6)0 (0.0)
BMI (kg/m2)31.1 ± 4.431.1 ± 4.530.7 ± 5.129.5 ± 3.8
Male/female56/2764/1861/2259/17
Duration of diabetes (years)5.1 ± 4.95.2 ± 4.77.5 ± 7.46.1 ± 5.5
Previous use of oral hypoglycemics agents
 None48 (57.8)42 (51.2)55 (66.3)46 (60.5)
 Metformin22 (26.5)18 (22.0)19 (22.9)16 (21.1)
 Sulphonylureas33 (39.8)25 (30.5)43 (51.8)35 (46.1)
HbAlc(%)8.1 ± 0.78.2 ± 0.98.2 ± 0.98.3 ± 0.8
  • Data are means ± SD and n (%). MIG, miglitol; MET, metformin.